Article Dans Une Revue Cardiovascular Research Année : 2021

Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)

Edina Cenko
Lina Badimon
Raffaele Bugiardini
Marc Claeys
Giuseppe de Luca
  • Fonction : Auteur
Cor de Wit
Maria Dorobantu
Dirk Duncker
Etto Eringa
Diana Gorog
Christian Hassager
Frank Heinzel
Kurt Huber
Olivia Manfrini
  • Fonction : Auteur
Davor Milicic
  • Fonction : Auteur
Evangelos Oikonomou
Teresa Padro
Danijela Trifunovic-Zamaklar
Zorana Vasiljevic-Pokrajcic
  • Fonction : Auteur
Marija Vavlukis
Gemma Vilahur
  • Fonction : Auteur
Dimitris Tousoulis

Résumé

Abstract The cardiovascular system is significantly affected in coronavirus disease-19 (COVID-19). Microvascular injury, endothelial dysfunction, and thrombosis resulting from viral infection or indirectly related to the intense systemic inflammatory and immune responses are characteristic features of severe COVID-19. Pre-existing cardiovascular disease and viral load are linked to myocardial injury and worse outcomes. The vascular response to cytokine production and the interaction between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and angiotensin-converting enzyme 2 receptor may lead to a significant reduction in cardiac contractility and subsequent myocardial dysfunction. In addition, a considerable proportion of patients who have been infected with SARS-CoV-2 do not fully recover and continue to experience a large number of symptoms and post-acute complications in the absence of a detectable viral infection. This conditions often referred to as ‘post-acute COVID-19’ may have multiple causes. Viral reservoirs or lingering fragments of viral RNA or proteins contribute to the condition. Systemic inflammatory response to COVID-19 has the potential to increase myocardial fibrosis which in turn may impair cardiac remodelling. Here, we summarize the current knowledge of cardiovascular injury and post-acute sequelae of COVID-19. As the pandemic continues and new variants emerge, we can advance our knowledge of the underlying mechanisms only by integrating our understanding of the pathophysiology with the corresponding clinical findings. Identification of new biomarkers of cardiovascular complications, and development of effective treatments for COVID-19 infection are of crucial importance.

Dates et versions

hal-04392249 , version 1 (13-01-2024)

Identifiants

Citer

Edina Cenko, Lina Badimon, Raffaele Bugiardini, Marc Claeys, Giuseppe de Luca, et al.. Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA). Cardiovascular Research, 2021, 117 (14), pp.2705-2729. ⟨10.1093/cvr/cvab298⟩. ⟨hal-04392249⟩

Collections

29 Consultations
0 Téléchargements

Altmetric

Partager

  • More